Skip to main content

Table 2 Treatment and efficacies of first-line chemoradiotherapy

From: Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study

  Overall Platinum group non-Platinum group P-value
n = 320 n = 119 n = 201
n % n % n %  
Platinum
 CDDP 189 59.1 68 57.1 121 60.2 0.21
 CBDCA 129 40.3 49 41.2 80 39.8
 Unknown 2 0.6 2 1.7 0 0
Radiation dose
  ≥ 60 Gy 271 84.7 96 80.7 175 87.1 0.10
  < 60 Gy 47 14.7 23 19.3 24 11.9
 Unknown 2 0.6 0 0 2 1.0  
Response to chemoradiotherapy
 ORR (%)   67.5   65.5   68.7 0.62
Duration from the start of first-line therapy to the start of second-line therapy
 Median (range), (months) 8.6 (0.5–46.2) 6.6 (0.5–46.2) 8.7 (0.5–38.0)  < 0.01
  1. CDDP cisplatin, CDBCA carboplatin, ORR objective response rate, Gy, gray
  2. P values were calculated using the Fisher’s exact test for categorical variables and with Mann–Whitney U test for continuous variables